Journal: Molecular cancer therapeutics

Article Title: Inhibition of SUMOylation Induces Adaptive Anti-Tumor Immunity Against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment

doi: 10.1158/1535-7163.MCT-23-0572

Figure Lengend Snippet: A. Log2 expression levels of SUMOylation-related genes in normal pancreas vs. pancreatic cancer using the database GENT2 ( 24 ). B. Kaplan-Meier curves showing the survival probability differences between groups with either high or low expression levels of SAE1 or UBC9 obtained using the Human Protein Atlas database. C. UMAP visualization plot of principle component analysis (PCA) on all cells from human patient data including 24 PDAC patient tumors and 11 non-PDAC human pancreas tissues ( 25 ). The cells are grouped into specific cell types. D. UMAP visualization plot of PCA on all cells from the same human samples as in (C). The cells are categorized as “normal” or “tumor” based on the origins of the cells. E. Feature plots of essential SUMOylation-related genes, UBA2 and UBE2I (UBC9), in the samples shown in (C). F. Violin plots of the SUMOylation-related genes in the same samples shown in (C) and (E).

Article Snippet: In addition, higher expression of the genes critical for SUMOylation, such as the activating enzyme (SAE) subunit SAE1 and the E2 enzyme UBE2I, correlated with worse survival, based on data from the Human Protein Atlas ( Fig. 1B ).

Techniques: Single-cell Transcriptomics, Expressing